Spectrum Could Sink On Aqaziquone Failure [View article]
It's going to be a good week for Spectrum! Index Funds buying to meet addition into S&P's smallcap index, and record earnings are forthcoming on Thursday. Income Hunter will become Income Loser! Hope to see some Short suffering Thursday and Friday.
4 Long And Short Trades You Can Make Monday Morning [View article]
They are nothing like Computer or Circuit City. Those dopes couldn't figure anything out. Muehlbauer states positive direction in the following comments going away from big box. Change is not immediate in this type of situation, but they are adapting!
A Quick Look At 8 Biotechs Ready To Gain Momentum [View article]
You can scratch SPPI off your list!
Spectrum Pharmaceuticals (SPPI) guides FY13 revenue below Street estimates, now anticipating total revenues in the range of $160M to $180M. Analysts were projecting FY13 revenue to come in at $297M
Athersys: An Undervalued Spec Company With High Potential [View article]
ZZ, Athersys is a risk, period. But it is a calculated risk. I'm investing in the potential of MultiStem's future. If it doesn't pan out, I move on. But right here and now, I love the potential of the science. If you invest in Biotechnology, you are a risk taker. If you don't like the risk, stick with researching and investing in Pfizer. That's your safer bet. Traders in Biotechnology love the opportunity to potentially invest in a 10 bagger. Good luck to you.
Athersys: An Undervalued Spec Company With High Potential [View article]
Great article, great stock. Been accumulating for months, expecting good things in the coming year. Hoping to hear on another new partnership in the coming months. Thanks for the research! don55, not sure what your broker is smoking?
A Comprehensive Analysis Of NPS Pharmaceuticals [View article]
Really Biomaster? Can you place yourself in these people's shoes? How many drugs are out there with numerous labels on them? Do you watch TV? I get sick of hearing all the deathly warnings spewed out on the many drugs advertised. Do you understand this statement?: There is no complete therapeutic cure for this disorder, and this disease is listed in the database of rare diseases that is maintained by the National Organization for Rare Disorders (or NORD) as well as Orphanet (orphan number ORPHA104008) which is a portal for rare diseases and orphan drugs. Where there is no medicinal cure now, do you believe these few thousand patients won't take a little risk for some physical benefit? Get Real!
Spectrum Could Sink On Aqaziquone Failure [View article]
Hope to see some Short suffering Thursday and Friday.
4 Long And Short Trades You Can Make Monday Morning [View article]
http://seekingalpha.co...
Athersys, Inc: The Facts [View article]
A Quick Look At 8 Biotechs Ready To Gain Momentum [View article]
Spectrum Pharmaceuticals (SPPI) guides FY13 revenue below Street estimates, now anticipating total revenues in the range of $160M to $180M. Analysts were projecting FY13 revenue to come in at $297M
Athersys: An Undervalued Spec Company With High Potential [View article]
Athersys is a risk, period. But it is a calculated risk. I'm investing in the potential of MultiStem's future. If it doesn't pan out, I move on. But right here and now, I love the potential of the science. If you invest in Biotechnology, you are a risk taker. If you don't like the risk, stick with researching and investing in Pfizer. That's your safer bet. Traders in Biotechnology love the opportunity to potentially invest in a 10 bagger.
Good luck to you.
'Top Of The Class' Small Pharma Investments For 2013 Part II [View article]
Athersys: An Undervalued Spec Company With High Potential [View article]
A Comprehensive Analysis Of NPS Pharmaceuticals [View article]
A Comprehensive Analysis Of NPS Pharmaceuticals [View article]
There is no complete therapeutic cure for this disorder, and this disease is listed in the database of rare diseases that is maintained by the National Organization for Rare Disorders (or NORD) as well as Orphanet (orphan number ORPHA104008) which is a portal for rare diseases and orphan drugs.
Where there is no medicinal cure now, do you believe these few thousand patients won't take a little risk for some physical benefit?
Get Real!
A Comprehensive Analysis Of NPS Pharmaceuticals [View article]
10 Recent CEO Insider Purchases To Consider [View article]
3 Small Pharma Companies With Major Catalysts In 2013 [View article]
Thanks for the quality write-up!
These CEOs Just Made Some Very Bullish Insider Purchases [View article]
Small Pharmaceuticals With Near Term Catalysts Offer Investment Opportunities [View article]
2 Speculative Biotech Plays Making Significant Strides [View article]